-+ 0.00%
-+ 0.00%
-+ 0.00%

Allarity says stenoparib DRP scores link to longer survival in ovarian cancer trial

PUBT·04/21/2026 12:05:51
Listen to the news
Allarity says stenoparib DRP scores link to longer survival in ovarian cancer trial
  • Allarity Therapeutics published two posters for presentation at AACR Annual Meeting 2026 in San Diego on April 17-22.
  • One poster reports results already presented linking higher stenoparib DRP scores with longer overall survival in a Phase 2 ovarian cancer trial of stenoparib.
  • Another poster to be presented April 21 outlines preclinical findings that stenoparib can modulate WNT signaling and curb growth in colorectal cancer cell lines at clinically relevant exposures.
  • Update positions stenoparib as a differentiated oral candidate in colorectal cancer while supporting DRP-based patient selection as a strategy to improve outcomes in ovarian cancer development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604210800PRIMZONEFULLFEED1001177002) on April 21, 2026, and is solely responsible for the information contained therein.